Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00950300
Registration number
NCT00950300
Ethics application status
Date submitted
30/07/2009
Date registered
31/07/2009
Date last updated
23/01/2018
Titles & IDs
Public title
A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer
Query!
Scientific title
A Phase III, Randomized Open-Label Study to Compare the Pharmacokinetics, Efficacy, and Safety of Subcutaneous (SC) Trastuzumab With Intravenous (IV) Trastuzumab Administered in Women With HER2-Positive Early Breast Cancer (EBC)
Query!
Secondary ID [1]
0
0
2008-007326-19
Query!
Secondary ID [2]
0
0
BO22227
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - 5-Fluorouracil
Treatment: Drugs - Cyclophosphamide
Treatment: Drugs - Docetaxel
Treatment: Drugs - Epirubicin
Treatment: Drugs - Herceptin IV [trastuzumab]
Treatment: Drugs - Herceptin SC [trastuzumab]
Active Comparator: Herceptin IV + Chemotherapy - Participants will receive Herceptin via IV infusion for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin IV will be given on Day 1 of each 21-day cycle, as 8 milligrams per kilogram (mg/kg) for a loading dose during Cycle 1 and as 6 mg/kg during subsequent cycles.
Experimental: Herceptin SC + Chemotherapy - Participants will receive Herceptin via SC injection for 8 cycles prior to surgery and an additional 10 cycles after surgery. Docetaxel will be co-administered during Cycles 1 to 4; chemotherapy during Cycles 5 to 8 will include 5-fluorouracil, cyclophosphamide, and epirubicin. Herceptin SC will be given on Day 1 of each 21-day cycle, as a 600-milligram (mg) fixed dose.
Treatment: Drugs: 5-Fluorouracil
Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Treatment: Drugs: Cyclophosphamide
Participants will receive cyclophosphamide, 500 mg/m^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Treatment: Drugs: Docetaxel
Participants will receive docetaxel, 75 mg/m^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
Treatment: Drugs: Epirubicin
Participants will receive epirubicin, 75 mg/m^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
Treatment: Drugs: Herceptin IV [trastuzumab]
Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
Treatment: Drugs: Herceptin SC [trastuzumab]
Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery
Query!
Assessment method [1]
0
0
Pre-dose samples were obtained prior to surgery (Cycle 8). The observed Ctrough was recorded, averaged among all participants, and expressed in micrograms per milliliter (µg/mL).
Query!
Timepoint [1]
0
0
Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Query!
Primary outcome [2]
0
0
Percentage of Participants With Pathological Complete Response (pCR)
Query!
Assessment method [2]
0
0
Participants were evaluated following eight cycles of treatment and after surgery to assess for pCR, defined as absence of neoplastic invasive cells in the breast according to pathologist examination. The percentage of participants with pCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.
Query!
Timepoint [2]
0
0
After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)
Query!
Secondary outcome [1]
0
0
Observed Ctrough of Trastuzumab After Surgery
Query!
Assessment method [1]
0
0
Pre-dose samples were obtained after surgery (Cycle 13). The observed Ctrough was recorded, averaged among all participants, and expressed in µg/mL.
Query!
Timepoint [1]
0
0
Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Query!
Secondary outcome [2]
0
0
Predicted Ctrough of Trastuzumab Prior to Surgery
Query!
Assessment method [2]
0
0
Predicted Ctrough at pre-dose prior to surgery (Cycle 8) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in µg/mL.
Query!
Timepoint [2]
0
0
Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Query!
Secondary outcome [3]
0
0
Predicted Ctrough of Trastuzumab After Surgery
Query!
Assessment method [3]
0
0
Predicted Ctrough at pre-dose after surgery (Cycle 13) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in µg/mL.
Query!
Timepoint [3]
0
0
Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Query!
Secondary outcome [4]
0
0
Number of Participants With Ctrough of Trastuzumab >20 µg/mL Prior to Surgery
Query!
Assessment method [4]
0
0
Pre-dose samples were obtained prior to surgery (Cycle 8). The number of participants who had an observed Ctrough >20 µg/mL was reported.
Query!
Timepoint [4]
0
0
Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Query!
Secondary outcome [5]
0
0
Number of Participants With Ctrough of Trastuzumab >20 µg/mL After Surgery
Query!
Assessment method [5]
0
0
Pre-dose samples were obtained after surgery (Cycle 13). The number of participants who had an observed Ctrough >20 µg/mL was reported.
Query!
Timepoint [5]
0
0
Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Query!
Secondary outcome [6]
0
0
Maximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery
Query!
Assessment method [6]
0
0
PK samples were obtained prior to surgery (Cycle 7). The Cmax during Cycle 7 was recorded, averaged among all participants, and expressed in µg/mL.
Query!
Timepoint [6]
0
0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Query!
Secondary outcome [7]
0
0
Time of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery
Query!
Assessment method [7]
0
0
PK samples were obtained prior to surgery (Cycle 7). The Tmax during Cycle 7 was recorded, averaged among all participants, and expressed in days.
Query!
Timepoint [7]
0
0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Query!
Secondary outcome [8]
0
0
Area Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery
Query!
Assessment method [8]
0
0
PK samples were obtained prior to surgery (Cycle 7). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 7 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in days multiplied by micrograms per milliliters (d*µg/mL).
Query!
Timepoint [8]
0
0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)
Query!
Secondary outcome [9]
0
0
Cmax of Trastuzumab After Surgery
Query!
Assessment method [9]
0
0
PK samples were obtained after surgery (Cycle 12). The Cmax during Cycle 12 was recorded, averaged among all participants, and expressed in µg/mL.
Query!
Timepoint [9]
0
0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Query!
Secondary outcome [10]
0
0
Tmax of Trastuzumab After Surgery
Query!
Assessment method [10]
0
0
PK samples were obtained after surgery (Cycle 12). The Tmax during Cycle 12 was recorded, averaged among all participants, and expressed in days.
Query!
Timepoint [10]
0
0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Query!
Secondary outcome [11]
0
0
AUC21d of Trastuzumab After Surgery
Query!
Assessment method [11]
0
0
PK samples were obtained after surgery (Cycle 12). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 12 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in d*µg/mL.
Query!
Timepoint [11]
0
0
Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)
Query!
Secondary outcome [12]
0
0
Percentage of Participants With Total Pathological Complete Response (tpCR)
Query!
Assessment method [12]
0
0
Participants were evaluated following eight cycles of treatment and after surgery to assess for tpCR, defined as absence of neoplastic invasive cells in the breast and axillary lymph nodes according to pathologist examination. The percentage of participants with tpCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.
Query!
Timepoint [12]
0
0
After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)
Query!
Secondary outcome [13]
0
0
Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline
Query!
Assessment method [13]
0
0
Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to less than (<) 10 millimeters (mm) with no prior assessment of progressive disease (PD). PR was defined as greater than or equal to (=) 30% decrease from Baseline in sum diameter (SD) of target lesions with no prior assessment of PD. PD was defined as =20% relative increase and =5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. The percentage of participants with overall response of CR or PR at the end of neoadjuvant treatment was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method.
Query!
Timepoint [13]
0
0
Tumor assessments at Baseline; on Day 1 of Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months overall)
Query!
Secondary outcome [14]
0
0
Time to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline
Query!
Assessment method [14]
0
0
Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to <10 mm with no prior assessment of PD. PR was defined as =30% decrease from Baseline in SD of target lesions with no prior assessment of PD. PD was defined as =20% relative increase and =5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. Time to response was defined as the time from first dose of study medication to the first assessment of CR or PR, which was the date the response was first documented by objective evidence, among participants with an overall response of CR or PR.
Query!
Timepoint [14]
0
0
Tumor assessments at Baseline; on Day 1 Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of chemotherapy (approximately 6 months overall)
Query!
Secondary outcome [15]
0
0
Percentage of Participants Who Experienced a Protocol-Defined Event
Query!
Assessment method [15]
0
0
Protocol-defined events included disease recurrence/progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. The percentage of participants who experienced a protocol-defined event at any time during the study was reported.
Query!
Timepoint [15]
0
0
Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Query!
Secondary outcome [16]
0
0
Event-Free Survival (EFS)
Query!
Assessment method [16]
0
0
Protocol-defined events included disease recurrence or progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. EFS was estimated by Kaplan-Meier analysis and defined as the time from randomization to the first protocol-defined event.
Query!
Timepoint [16]
0
0
Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Query!
Secondary outcome [17]
0
0
Percentage of Participants Who Died
Query!
Assessment method [17]
0
0
The percentage of participants who died at any time during the study was reported.
Query!
Timepoint [17]
0
0
Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Query!
Secondary outcome [18]
0
0
Overall Survival (OS)
Query!
Assessment method [18]
0
0
OS was estimated by Kaplan-Meier analysis and defined as the time from randomization to death from any cause.
Query!
Timepoint [18]
0
0
Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)
Query!
Secondary outcome [19]
0
0
Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab
Query!
Assessment method [19]
0
0
Participants provided PK samples for evaluation of anti-trastuzumab antibodies. The number of participants with "Treatment-induced ADAs" and "Treatment-enhanced ADA" against trastuzumab at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).
Query!
Timepoint [19]
0
0
Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18
Query!
Secondary outcome [20]
0
0
Number of Participants With ADAs Against Recombinant Human Hyaluronidase (rHuPH20)
Query!
Assessment method [20]
0
0
Participants in the Herceptin SC arm provided PK samples for evaluation of anti-rHuPH20 antibodies. The number of participants with "Treatment-induced ADAs" and "Treatment-enhanced ADA" against rHuPH20 (an excipient unique to the SC formulation) at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer).
Query!
Timepoint [20]
0
0
Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18
Query!
Eligibility
Key inclusion criteria
- Adult women greater than or equal to (=) 18 years of age
- Non-metastatic primary invasive adenocarcinoma of the breast clinical stage I to IIIC,
including inflammatory and multicentric/multifocal breast cancer, with tumor size =1
centimeter (cm) by ultrasound or =2 cm by palpation, centrally confirmed HER2-positive
(immunohistochemical score [IHC] 3+ or in situ hybridization [ISH]-positive)
- At least 1 measurable lesion in breast or lymph nodes (=1 cm by ultrasound or =2 cm by
palpation), except for inflammatory carcinoma (T4d)
- Baseline left ventricular ejection fraction (LVEF) =55%
- Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
- Adequate organ function at Baseline
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- History of any prior (ipsilateral and/or contralateral) invasive breast carcinoma
- Past or current history of malignant neoplasms, except for curatively treated basal
and squamous cell carcinoma of the skin and in situ carcinoma of the cervix
- Metastatic disease
- Any prior therapy with anthracyclines
- Prior anti-HER2 therapy or biologic or immunotherapy
- Serious cardiac illness
- Pregnant or lactating women
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/10/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
24/01/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
596
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
Argentina
Query!
State/province [1]
0
0
Tucuman
Query!
Country [2]
0
0
Brazil
Query!
State/province [2]
0
0
BA
Query!
Country [3]
0
0
Brazil
Query!
State/province [3]
0
0
PR
Query!
Country [4]
0
0
Brazil
Query!
State/province [4]
0
0
RN
Query!
Country [5]
0
0
Brazil
Query!
State/province [5]
0
0
SC
Query!
Country [6]
0
0
Brazil
Query!
State/province [6]
0
0
SP
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Quebec
Query!
Country [8]
0
0
Colombia
Query!
State/province [8]
0
0
Bogota
Query!
Country [9]
0
0
Colombia
Query!
State/province [9]
0
0
Pereira
Query!
Country [10]
0
0
Czechia
Query!
State/province [10]
0
0
Olomouc
Query!
Country [11]
0
0
Czechia
Query!
State/province [11]
0
0
Pardubice
Query!
Country [12]
0
0
Czechia
Query!
State/province [12]
0
0
Praha
Query!
Country [13]
0
0
Estonia
Query!
State/province [13]
0
0
Tallinn
Query!
Country [14]
0
0
Estonia
Query!
State/province [14]
0
0
Tartu
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Besancon
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Grenoble
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
La Tronche
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Le Mans
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
Paris
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Reims
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
St Cloud
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Berlin
Query!
Country [23]
0
0
Germany
Query!
State/province [23]
0
0
Bonn
Query!
Country [24]
0
0
Germany
Query!
State/province [24]
0
0
Dortmund
Query!
Country [25]
0
0
Germany
Query!
State/province [25]
0
0
Hannover
Query!
Country [26]
0
0
Germany
Query!
State/province [26]
0
0
Leipzig
Query!
Country [27]
0
0
Germany
Query!
State/province [27]
0
0
Lemgo
Query!
Country [28]
0
0
Germany
Query!
State/province [28]
0
0
Offenbach
Query!
Country [29]
0
0
Germany
Query!
State/province [29]
0
0
Rodewisch
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Tübingen
Query!
Country [31]
0
0
Guatemala
Query!
State/province [31]
0
0
Guatemala
Query!
Country [32]
0
0
Hong Kong
Query!
State/province [32]
0
0
Hong Kong
Query!
Country [33]
0
0
Hungary
Query!
State/province [33]
0
0
Budapest
Query!
Country [34]
0
0
Hungary
Query!
State/province [34]
0
0
Gyor
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Szeged
Query!
Country [36]
0
0
Israel
Query!
State/province [36]
0
0
Jerusalem
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Petach Tikva
Query!
Country [38]
0
0
Italy
Query!
State/province [38]
0
0
Campania
Query!
Country [39]
0
0
Italy
Query!
State/province [39]
0
0
Lombardia
Query!
Country [40]
0
0
Korea, Republic of
Query!
State/province [40]
0
0
Incheon
Query!
Country [41]
0
0
Korea, Republic of
Query!
State/province [41]
0
0
Seoul
Query!
Country [42]
0
0
Mexico
Query!
State/province [42]
0
0
Obregon
Query!
Country [43]
0
0
Mexico
Query!
State/province [43]
0
0
Toluca
Query!
Country [44]
0
0
Panama
Query!
State/province [44]
0
0
Panama
Query!
Country [45]
0
0
Peru
Query!
State/province [45]
0
0
Arequipa
Query!
Country [46]
0
0
Peru
Query!
State/province [46]
0
0
Lima
Query!
Country [47]
0
0
Peru
Query!
State/province [47]
0
0
Piura
Query!
Country [48]
0
0
Peru
Query!
State/province [48]
0
0
San Isidro
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Elblag
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Lublin
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Olsztyn
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Warszawa
Query!
Country [53]
0
0
Russian Federation
Query!
State/province [53]
0
0
Leningrad
Query!
Country [54]
0
0
Russian Federation
Query!
State/province [54]
0
0
Ivanovo
Query!
Country [55]
0
0
Russian Federation
Query!
State/province [55]
0
0
Moscow
Query!
Country [56]
0
0
Russian Federation
Query!
State/province [56]
0
0
Pyatigorsk
Query!
Country [57]
0
0
Russian Federation
Query!
State/province [57]
0
0
Ryazan
Query!
Country [58]
0
0
Russian Federation
Query!
State/province [58]
0
0
Samara
Query!
Country [59]
0
0
Russian Federation
Query!
State/province [59]
0
0
Saratov
Query!
Country [60]
0
0
Russian Federation
Query!
State/province [60]
0
0
St Petersburg
Query!
Country [61]
0
0
Russian Federation
Query!
State/province [61]
0
0
Stavropol
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Tula
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Vladimir
Query!
Country [64]
0
0
Slovakia
Query!
State/province [64]
0
0
Kosice
Query!
Country [65]
0
0
Slovakia
Query!
State/province [65]
0
0
Poprad
Query!
Country [66]
0
0
South Africa
Query!
State/province [66]
0
0
Bloemfontein
Query!
Country [67]
0
0
South Africa
Query!
State/province [67]
0
0
Cape Town
Query!
Country [68]
0
0
South Africa
Query!
State/province [68]
0
0
Parktown, Johannesburg
Query!
Country [69]
0
0
South Africa
Query!
State/province [69]
0
0
Pretoria
Query!
Country [70]
0
0
South Africa
Query!
State/province [70]
0
0
Rondebosch
Query!
Country [71]
0
0
South Africa
Query!
State/province [71]
0
0
Sandton
Query!
Country [72]
0
0
Spain
Query!
State/province [72]
0
0
LA Coruña
Query!
Country [73]
0
0
Spain
Query!
State/province [73]
0
0
Tarragona
Query!
Country [74]
0
0
Spain
Query!
State/province [74]
0
0
Madrid
Query!
Country [75]
0
0
Spain
Query!
State/province [75]
0
0
Valencia
Query!
Country [76]
0
0
Spain
Query!
State/province [76]
0
0
Zaragoza
Query!
Country [77]
0
0
Sweden
Query!
State/province [77]
0
0
Lund
Query!
Country [78]
0
0
Sweden
Query!
State/province [78]
0
0
Uppsala
Query!
Country [79]
0
0
Taiwan
Query!
State/province [79]
0
0
Changhua
Query!
Country [80]
0
0
Taiwan
Query!
State/province [80]
0
0
Taipei City
Query!
Country [81]
0
0
Taiwan
Query!
State/province [81]
0
0
Taipei
Query!
Country [82]
0
0
Taiwan
Query!
State/province [82]
0
0
Taoyuan
Query!
Country [83]
0
0
Thailand
Query!
State/province [83]
0
0
Bangkok
Query!
Country [84]
0
0
Thailand
Query!
State/province [84]
0
0
Songkhla
Query!
Country [85]
0
0
Turkey
Query!
State/province [85]
0
0
Antalya
Query!
Country [86]
0
0
Turkey
Query!
State/province [86]
0
0
Istanbul
Query!
Country [87]
0
0
Turkey
Query!
State/province [87]
0
0
Izmir
Query!
Country [88]
0
0
Turkey
Query!
State/province [88]
0
0
Sihhiye, Ankara
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
In this open-label multicenter trial, participants with operable or locally advanced breast
cancer will be randomized to pre-operative treatment with 8 cycles of chemotherapy (4 cycles
of docetaxel followed by 4 cycles of 5-fluorouracil, epirubicin, and cyclophosphamide)
concurrent with either SC Herceptin or IV Herceptin. After surgery, participants will receive
a further 10 cycles of SC or IV Herceptin as per randomization to complete 1 year of
treatment. All cycles will be 21 days in length. After the end of study treatment,
participants will be followed for safety and efficacy for up to 5 years or until disease
recurrence, whichever is earlier.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00950300
Query!
Trial related presentations / publications
Query!
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00950300
Download to PDF